You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD22-CART

Showing 1 - 25 of 8,376
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)

Unknown status
  • Leukemia
  • Lymphoma
  • Anti-CD22-CAR-transduced T cells
  • Beijing, Beijing, China
    Fengtai District
Feb 6, 2021

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22

Recruiting
  • B Cell Leukemias
  • B Cell Lymphomas
  • CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 19, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Adult B Acute Lymphoblastic Leukemia Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

Recruiting
  • Adult B Acute Lymphoblastic Leukemia
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

Study for Patients Treat With WU-CART-007

Enrolling by invitation
  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma
  • Genetic: WU-CART-007
  • Saint Louis, Missouri
    Washington University
Aug 18, 2022

B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

Suspended
  • B Cell Lymphoma
  • +2 more
  • Stanford, California
    Stanford Medical Center
Sep 8, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • CD19x22 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022